Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Aravive Shares Rise on Positive Patient Data from Phase 1b Ovarian Cancer Study

Shares of Aravive Inc. are trading higher after the firm posted positive data from the initial 12 patients enrolled in the Phase 1b portion of its study of AVB-500 used in the treatment of ovarian cancer. Today, in a late-breaking oral presentation at the European Soc...
Streetwise Reports | September 30, 2019 |

Iovance Biotherapeutics Shares Rise 12% on Updated Phase 2 Melanoma Study Results

Shares of Iovance Biotherapeutics traded 12% higher today after the firm reported updated clinical data from its phase 2 lifileucel metastatic melanoma trial. Just a few days after reporting third quarter 2019 earnings, late-stage biotechnology company Iovance Biothe...
Streetwise Reports | November 12, 2019 |

Protagonist Therapeutics Shares Trade Up 70% on Phase 2 Transfusion Trial Results

Newark, Calif.-based Protagonist Therapeutics' shares traded 70% higher today after the firm reported preliminary Phase 2 results for Hepcidin Mimetic PTG-300 in the treatment of transfusion dependent beta-thalassemia. Clinical-stage biopharmaceutical company Protago...
Streetwise Reports | December 5, 2019 |

Novamind Selected by Merck to Advance Research for Treatment-Resistant Depression

Novamind’s subsidiary, Cedar Clinical Research, to serve as a key clinical research site Independent validation of the expertise and capabilities of Novamind in managing clinical trials Adds to established track record conducting research a...
Featured Submission | March 18, 2021 |

Allakos Shares Double on AK002 Phase 2 Results and Earnings

Allakos Inc. shares are soaring today as the company reported Q2/19 earnings and announced positive results from its phase 2 study for its AK002 inhibitor used in the treatment of eosinophil and mast cell related diseases. Clinical stage biotech company Allak...
Streetwise Reports | August 7, 2019 |

Regeneron Reports Positive Phase 3 Dupixent Data; Gains EU Approval Recommendation

Regeneron Pharmaceuticals published positive results from two U.S. Phase 3 trials evaluating the safety and efficacy of Dupixent (dupilumab) in adults with recurring severe chronic rhinosinusitis with nasal polyps. The European Medicines Agency's Committee for Medicinal Produc...
Streetwise Reports | September 24, 2019 |

Dermira's Phase 2b Atopic Dermatitis Trial Results Send Shares 25% Higher

Dermira shares traded higher today after the firm released positive data from its phase 2b study of lebrikizumab in patients with atopic dermatitis at the Las Vegas Fall Clinical Dermatology Conference. Yesterday afternoon, Dermira Inc. (DERM:NASDAQ) , a biopharmaceu...
Streetwise Reports | October 21, 2019 |

Biogen Shares Rebound Strongly on Updated Phase 3 Alzheimer's Data and Q3 Earnings

Shares of Biogen Inc. opened nearly 39% higher today after the firm announced plans to submit a Biologics License Application to the FDA in early 2020 for its Alzheimer's drug aducanumab based on new analysis of larger datasets from two phase 3 studies. The company also anno...
Streetwise Reports | October 23, 2019 |

RedHill Biopharma Shares Rise 10% After Receiving FDA Approval for H. Pylori Treatment Drug Talicia

Shares of RedHill Biopharma Ltd. traded more than 10% higher today after the firm announced that the FDA has approved its Talicia delayed-release capsules for the treatment of H. pylori infection in adults. The firm plans to commence distribution by its U.S. sales force in Q1/...
Streetwise Reports | November 5, 2019 |

Biopharma Continues 'Positive Push Forward in Breast Cancer'

The latest clinical trial results and next step are reviewed in an H.C. Wainwright & Co. report. In a Dec. 26 research note, analyst Joseph Pantginis reported that H.C. Wainwright & Co. increased its target price to AU$0.20 from AU$0.16 and maintained its Buy recommen...
Streetwise Reports | December 30, 2019 |
1 2 3 4 5 6 7 8 9 10 ...